Standardizing biomarker testing for Canadian patients with advanced lung cancer

BACKGROUND: The development and approval of both targeted and immune therapies for patients with advanced non-small cell lung cancer (nsclc) has significantly improved patient survival rates and quality of life. Biomarker testing for patients newly diagnosed with nsclc, as well as for patients progr...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Curr Oncol
Main Authors: Melosky, B., Blais, N., Cheema, P., Couture, C., Juergens, R., Kamel-Reid, S., Tsao, M.-S., Wheatley-Price, P., Xu, Z., Ionescu, D.N.
Format: Artigo
Jezik:Inglês
Izdano: Multimed Inc. 2018
Teme:
Practice Guideline
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5832280/
https://ncbi.nlm.nih.gov/pubmed/29507487
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.25.3867
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki